Stock market today: S&P 500 closes at fresh record ahead of Nvidia earnings
WARSAW, Ind. - OrthoPediatrics Corp. (NASDAQ:KIDS), a medical device company with a market capitalization of approximately $510 million, announced Monday the appointment of Kelly Fischer to its Board of Directors, effective August 8, 2025. The appointment coincides with the retirement of Terry Schlotterback from the board after more than 15 years of service. According to InvestingPro analysis, the company maintains a Fair overall financial health rating, with liquid assets exceeding short-term obligations.
Fischer currently serves as Senior Vice President and Chief Financial Officer at Cook Medical, a multibillion-dollar medical device company where she has worked for over two decades in various finance and operations roles. Prior to Cook Medical, Fischer worked as an Audit Manager at Ernst & Young and held positions at Arthur Andersen. She holds a bachelor’s degree in accounting from Indiana University’s Kelley School of Business.
Mark Throdahl, Executive Chairman of OrthoPediatrics’ Board of Directors, cited Fischer’s financial leadership experience as an asset to the company’s strategic execution and expansion efforts.
Schlotterback, who served as both a Director and Chairman of the Board during his tenure, was recognized for his contributions to establishing the company in the pediatric orthopedic market.
OrthoPediatrics, founded in 2006, focuses exclusively on pediatric orthopedics and currently markets over 80 products across trauma and deformity, scoliosis, and sports medicine categories. The company distributes its products in the United States and more than 70 countries worldwide.
The information in this article is based on a press release statement from OrthoPediatrics Corp.
In other recent news, OrthoPediatrics Corporation reported its second-quarter 2025 earnings, showcasing a notable earnings per share (EPS) of -$0.11, which significantly surpassed the forecasted -$0.29. Despite this positive earnings surprise, the company’s quarterly revenue of $61.1 million, marking a 16% year-over-year growth, fell short of the consensus estimate of $62.5 million. The Trauma & Deformity segment contributed $41.7 million to the revenue, up 10.3% from the previous year, while Scoliosis sales rose by 35.4% to $18.5 million. However, the Sports Medicine/Other segment saw a decline, with sales dropping 32.9% to $0.9 million.
Following these results, Citizens JMP adjusted its price target for OrthoPediatrics, lowering it from $50.00 to $35.00, yet maintaining a Market Outperform rating. Similarly, BTIG revised its price target from $40.00 to $39.00, keeping a Buy rating intact. These adjustments reflect the mixed results from the quarter, with both firms acknowledging the revenue shortfall despite the earnings beat. These developments provide investors with crucial insights into OrthoPediatrics’ recent performance and analyst expectations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.